According to the American Pharmacists Association, as of late July, Alirocumab, a PCSK9 inhibitor, obtained FDA approval. In addition to diet and aggressive statin therapy, Alirocumab acts as an aid for patients that have clinical atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. These patients are required to lower their cholesterol further. Alirocumab, a monoclonal antibody which is self-administered through subcutaneious injection every two weeks, lowers cholesterol by inhibiting PCSK9, whose primary purpose in the body is to reduce the receptors in the liver that dispose of LDL from the bloodstream. LDL is low-density lipoproteins that are considered “bad’ protein because they can collect on the walls of blood vessels, which, if untreated, can cause blockages. Since alirocumab acts to block PCSK9, alirocumab would free up a numerous LDL receptors that are able to clear LDL from the bloodstream. Studies have shown that alirocumab and statins reduce LDL considerably; however, the effects of cardiovascular morbidity and mortality are still present.
…show more content…
The program included several clinical trials (5 key trials) and encompassed roughly 3,500 patients. In conjunction with standard care, alirocumab demonstrated during the twenty fourth weeks on the trial that there was a reduction of LDL. This study was compared to two control groups: a group that received a placebo and one that received standard care. The American Pharmacists Association states that LDL was reduced by 36 to 58 percent across the five studies, illustrating the effectiveness of alirocumab working with statins. Nevertheless, there were common adverse reactions, such as nasopharyngitis, influenza, and injection site
The program included several clinical trials (5 key trials) and encompassed roughly 3,500 patients. In conjunction with standard care, alirocumab demonstrated during the twenty fourth weeks on the trial that there was a reduction of LDL. This study was compared to two control groups: a group that received a placebo and one that received standard care. The American Pharmacists Association states that LDL was reduced by 36 to 58 percent across the five studies, illustrating the effectiveness of alirocumab working with statins. Nevertheless, there were common adverse reactions, such as nasopharyngitis, influenza, and injection site